Ustekinumab Plus Prednisone Versus Prednisone Alone for Refractory Giant Cell Arteritis: a Randomized Phase IIb Open-Label Trial (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1896; Pres time: Nov 9, 2026; 02:00 PM - 02:15 PM; Location: W415BC; In Person; P2 | "At inclusion (UST vs control), baseline characteristics were similar: median disease duration was 2.2 vs 1.3 years; the current relapse was the first in 55% vs 59% of patients; and 25% vs 18% had prior immunosuppressive therapy (methotrexate 20% vs 18%; tocilizumab 10% vs 0%). In this first randomized trial of an anti‑IL‑12/23 agent in GCA, UST plus prednisone significantly increased sustained remission at W52 versus prednisone alone in relapsing GCA, with acceptable safety. These findings support a role for IL‑12/23 in GCA and justify a phase III trial, possibly with extended dosing."
Clinical • P2b data • Giant Cell Arteritis • Immunology • Infectious Disease • Pneumonia • Respiratory Diseases • IL12A
|
|
Maxime SAMSON1; Abderrahmane Bourredjem2; Thomas Moulinet3; Mihaela-Liana VOICU4; Thibault MAILLET5; Amélie SERVETTAZ6; Julien CAMPAGNE7; Aurélien GUFFROY8; Isabelle FOURNEL9; Hervé DEVILLIERS9; Bertrand Bonnotte1
|